Surfactant without intubation in preterm infants with respiratory distress: first multi-center data.
Angela Kribs, C Härtel, E Kattner...
https://pubmed.ncbi.nlm.nih.gov/20084586/Actively Recruiting
Led by Endeavor Health · Updated on 2025-08-07
200
Participants Needed
1
Research Sites
82 weeks
Total Duration
Researchers are investigating whether giving surfactant early in the delivery room using a minimally invasive technique helps improve outcomes for preterm infants born between 22 and 29 weeks of gestation compared to waiting to treat only if needed. This randomized, controlled trial involves multiple hospitals and aims to determine if early surfactant reduces the need for intubation in these very premature babies. In this study, babies are randomly assigned to receive poractant alfa Curosurf surfactant within 15 minutes after birth using a special catheter for minimally invasive surfactant therapy MIST, or to receive the same treatment only if their oxygen needs rise above a certain level within the first 48 hours. Both groups will be supported with nasal continuous positive airway pressure NCPAP or high flow nasal cannula HFNC. A second surfactant dose may be given if oxygen requirements increase again between 6 and 48 hours after the first dose. Babies needing emergency intubation at birth are not included in the treatment part of the trial. Participants will be monitored closely in the neonatal intensive care unit with ongoing respiratory support as needed. Researchers will track whether infants need intubation within the first week, along with other respiratory and non-respiratory health outcomes until hospital discharge. Developmental follow-up assessments at two years corrected age will also be collected. The study plans to enroll about 200 infants over two years to evaluate the impact of early versus rescue surfactant treatment.
CONDITIONS
Prophylactic Minimally Invasive Surfactant Evaluation
M
Matthew Derrick, MBBS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Endeavor Health
Lead Sponsor
Chiesi USA, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Immediate Prophylactic Surfactant via Minimally Invasive Technique | Rescue Surfactant via Minimally Invasive Technique |
|---|---|---|
| What it is | Immediate delivery of Poractant Alfa (surfactant) using a minimally invasive catheter right after birth in preterm infants. | Poractant Alfa (surfactant) administered via minimally invasive catheter only if respiratory distress occurs after birth. |
| Role in trial | To test whether early surfactant delivery can prevent respiratory distress and reduce the need for intubation. | To assess if waiting to deliver surfactant until after respiratory distress allows for fewer interventions with comparable outcomes. |
| Primary use | Used to lower the risk of respiratory failure by providing surfactant before symptoms appear in high-risk preterm newborns. | Used to treat established respiratory distress syndrome, aiming to reduce severity and support lung function as symptoms develop. |
| How it is given or performed | Surfactant instilled using a catheter under direct laryngoscopy soon after birth in eligible infants. | Surfactant administered by catheter under laryngoscopy if respiratory distress appears after birth. |
| Important risks | Potential risks include airway complications, accidental injury during catheter placement, and surfactant-related reactions, but published trials report these events as relatively uncommon in skilled hands. | Risks are similar, including airway trauma and procedural complications, especially if distress is later and the infant is less stable. |
| Important limitations | Early prophylactic treatment may lead to unnecessary intervention in infants who would not develop significant distress, increasing resource use and potential exposure without clear benefit in all cases. | Waiting for symptoms may delay therapy, leading to more severe illness or higher intubation rates in some infants compared to early prophylaxis. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 2 weeks prior to delivery
Participants are screened for eligibility to participate in the trial.
1 visit for antenatal consent
Duration - Up to 48 hours after birth
Participants receive surfactant treatment either prophylactically within 15 minutes of delivery or as rescue treatment within the first 48 hours if oxygen needs increase.
1 treatment administration visit; additional dose if oxygen criteria met between 6 and 48 hours
Duration - Until hospital discharge and 2 years corrected age for developmental follow-up
Participants are monitored for respiratory and other health outcomes including intubation, bronchopulmonary dysplasia, and other neonatal morbidities until hospital discharge and developmental follow-up at 2 years corrected age.
Regular clinical assessments during hospital stay and 1 developmental follow-up visit at 2 years corrected age
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Angela Kribs, C Härtel, E Kattner...
https://pubmed.ncbi.nlm.nih.gov/20084586/J W Kendig, R H Notter, C Cox...
https://pubmed.ncbi.nlm.nih.gov/2000109/SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Neil N Finer, Waldemar A Carlo...
https://pubmed.ncbi.nlm.nih.gov/20472939/J Kattwinkel, B T Bloom, P Delmore...
https://pubmed.ncbi.nlm.nih.gov/8516091/Peter A Dargaville, C Omar F Kamlin, Francesca Orsini...
https://pubmed.ncbi.nlm.nih.gov/34902013/Endeavor Health
Lead Sponsor
Chiesi USA, Inc.
Collaborating Sponsor